(Q45327842)

13 December 2017

title

An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors (English)

1 reference

13 December 2017

1 reference

Yan Li

1

1 reference

13 December 2017

Weimin Gao

2

1 reference

13 December 2017

Feng Li

3

1 reference

13 December 2017

Jinghui Wang

4

1 reference

13 December 2017

Jingxiao Zhang

5

1 reference

13 December 2017

Yinfeng Yang

6

1 reference

13 December 2017

Shuwei Zhang

7

1 reference

13 December 2017

Ling Yang

8

1 reference

13 December 2017

publication date

1 September 2013

1 reference

13 December 2017

1 reference

13 December 2017

volume

9

1 reference

13 December 2017

issue

9

1 reference

13 December 2017

page(s)

2266-2281

1 reference

Platelet-derived growth factor--an introduction

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

G1 events and regulation of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

To cycle or not to cycle: a critical decision in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Differential requirement of cyclin-dependent kinase 2 for oligodendrocyte progenitor cell proliferation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Whether to target single or multiple CDKs for therapy? That is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

The CDK inhibitors in cancer research and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Perspectives for cancer therapies with cdk2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Overexpression of CDK2 is a prognostic indicator of oral cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Cyclin-dependent kinase inhibitors as anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Genome-wide metabolic network reconstruction of the picoalga Ostreococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

A combination of 3D-QSAR, docking, local-binding energy (LBE) and GRID study of the species differences in the carcinogenicity of benzene derivatives chemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

3D-QSAR study on atmospheric half-lives of POPs using CoMFA and CoMSIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Structural determination of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Isolation, biological evaluation and 3D-QSAR studies of insecticidal/narcotic sesquiterpene polyol esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

QSAR in the pharmaceutical research setting: QSAR models for broad, large problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Volume learning algorithm significantly improved PLS model for predicting the estrogenic activity of xenoestrogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Combined 3D-QSAR, molecular docking and molecular dynamics study on derivatives of peptide epoxyketone and tyropeptin-boronic acid as inhibitors against the β5 subunit of human 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

GROMACS: A message-passing parallel molecular dynamics implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

PRODRG: a tool for high-throughput crystallography of protein-ligand complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Computational drug design accommodating receptor flexibility: the relaxed complex scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

On two novel parameters for validation of predictive QSAR models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Pharmacological inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

A novel binding pocket of cyclin-dependent kinase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Discovery of a Potential Allosteric Ligand Binding Site in CDK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

A Novel Approach to the Discovery of Small-Molecule Ligands of CDK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Quinazolines as cyclin dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

Exploring QSAR on 3-aminopyrazoles as antitumor agents for their inhibitory activity of CDK2/cyclin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

GROMACS 3.0: a package for molecular simulation and trajectory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3MB70186G

21 January 2018

Identifiers

DOI

10.1039/C3MB70186G

1 reference

13 December 2017

1 reference